J&J qui­et­ly punts a pair of ear­ly-stage bis­pecifics for sol­id tu­mors

John­son & John­son has put two ear­ly-stage bis­pe­cif­ic an­ti­bod­ies on the back­burn­er, the phar­ma gi­ant re­vealed as part of its quar­ter­ly up­date.

List­ed in the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER